Stem Cells Spin Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Stem Cells Spin has been growing earnings at an average annual rate of 32.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 10.9% per year.
Belangrijke informatie
32.3%
Groei van de winst
32.3%
Groei van de winst per aandeel
| Biotechs Groei van de industrie | 56.3% |
| Inkomstengroei | -10.9% |
| Rendement op eigen vermogen | -4.9% |
| Nettomarge | -158.0% |
| Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Opbrengsten en kosten
Hoe Stem Cells Spin geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 0 | 0 | 0 | 0 |
| 31 Mar 24 | 0 | 0 | 0 | 0 |
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | 0 | 0 | 0 |
| 31 Dec 22 | 0 | 0 | 0 | 0 |
| 30 Sep 22 | 0 | 0 | 0 | 0 |
| 30 Jun 22 | 0 | 0 | 0 | 0 |
| 31 Mar 22 | 0 | 0 | 0 | 0 |
| 31 Dec 21 | 1 | 0 | 0 | 0 |
| 30 Sep 21 | 1 | 0 | 0 | 0 |
| 30 Jun 21 | 0 | 0 | 0 | 0 |
| 31 Mar 21 | 0 | 0 | 0 | 0 |
| 31 Dec 20 | 0 | 0 | 0 | 0 |
| 30 Sep 20 | 0 | 0 | 0 | 0 |
| 30 Jun 20 | 0 | 0 | 0 | 0 |
| 31 Mar 20 | 1 | -1 | 0 | 0 |
| 31 Dec 19 | 1 | -1 | 0 | 0 |
| 30 Sep 19 | 1 | -1 | 0 | 0 |
| 30 Jun 19 | 0 | -1 | 0 | 0 |
| 31 Mar 19 | 0 | -1 | 0 | 0 |
| 31 Dec 18 | 1 | -1 | 0 | 0 |
| 30 Sep 18 | 1 | 0 | 0 | 0 |
| 30 Jun 18 | 1 | 0 | 0 | 0 |
| 31 Mar 18 | 1 | 0 | 0 | 0 |
| 31 Dec 17 | 0 | 0 | 0 | 0 |
| 30 Sep 17 | 1 | 0 | 0 | 0 |
| 30 Jun 17 | 1 | 0 | 0 | 0 |
| 31 Mar 17 | 1 | 0 | 0 | 0 |
| 31 Dec 16 | 1 | 0 | 0 | 0 |
| 30 Sep 16 | 1 | 1 | 1 | 0 |
| 30 Jun 16 | 2 | 1 | 1 | 0 |
| 31 Mar 16 | 2 | 1 | 1 | 0 |
| 31 Dec 15 | 2 | 1 | 1 | 0 |
| 30 Sep 15 | 1 | 0 | 1 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 1 | 0 | 0 | 0 |
| 30 Sep 14 | 1 | 0 | 0 | 0 |
| 30 Jun 14 | 1 | 0 | 0 | 0 |
| 31 Mar 14 | 1 | 0 | 1 | 0 |
| 31 Dec 13 | 1 | 0 | 1 | 0 |
Kwaliteitswinsten: SCS is currently unprofitable.
Groeiende winstmarge: SCS is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: SCS is unprofitable, but has reduced losses over the past 5 years at a rate of 32.3% per year.
Versnelling van de groei: Unable to compare SCS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: SCS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
Rendement op eigen vermogen
Hoge ROE: SCS has a negative Return on Equity (-4.93%), as it is currently unprofitable.